ADAP.Y Share Price Performance
US$0.043
-0.79 (-94.83%)
95.6% undervalued intrinsic discount
US$0.98
Fair Value
Price US$0.043
AnalystConsensusTarget US$0.98
Fair ValueUS$0.98
Share PriceUS$0.043
95.6% undervalued intrinsic discount
Adaptimmune Therapeutics plc Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 24 Fair Values set on narratives written by author
ADAP.Y Community Narratives
AN
Fair Value US$0.98 95.6% undervalued intrinsic discount
ADAP.Y: Compliance Efforts Will Overcome Index Removal To Drive Recovery
0users have liked this narrative
0users have commented on this narrative
13users have followed this narrative
ADAP.Y: Compliance Efforts Will Overcome Index Removal To Drive Recovery
Key Takeaways Rapid treatment network expansion and successful TECELRA launch are driving significant future revenue growth and patient access. Strategic cost reductions and successful manufacturing are enhancing net margins and paving the way towards long-term profitability.Read more
0users have liked this narrative
0users have commented on this narrative
13users have followed this narrative
AN
US$0.98
95.6% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
44.82% p.a.
Profit Margin
16.4%
Future PE
12.92x
Share price in 2028
US$1.42
Snowflake Analysis
Adaptimmune Therapeutics plc Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- -0.64
- -97.73%
- -260.82%
- -36.2%
About ADAP.Y
- Founded
- 2008
- Employees
- 506
- CEO
- WebsiteView website
Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company also focuses on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520). It has strategic collaboration with Galapagos to clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel produced on Galapagos’ decentralized manufacturing platform (ADP-5701) in patients with head and neck cancer; collaboration and license agreement with Noile-Immune Biotech, Inc. and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
